INTRODUCTION OF A RANGE OF L-CYSTEINE DERIVATIVES AS NUTRITIONAL ADDITIVES IN PET FOOD, TO REDUCE OBESITY AND LENGTHEN ANIMAL LIFE
Ended · Spain
Source: EU Funding & Tenders Portal
Veterinary research shows that up to 45% of cats and dogs suffer health disorders, with oxidative effects from nutritional imbalances as a significant contributing factor. Of the approximately 270 million pets in the EU, 60% have commercial pet food exclusively as their source of nutrition and therefore depend on a complete and balanced product for health and wellbeing. The PetLife project is base
- Status
- Closed
- Sector
- Manufacturing (Industrial), Commercial
- Location
- Spain
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about INTRODUCTION OF A RANGE OF L-CYSTEINE DERIVATIVES AS NUTRITIONAL ADDITIVES IN PET FOOD, TO REDUCE OBESITY AND LENGTHEN ANIMAL LIFE
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | Veterinary research shows that up to 45% of cats and dogs suffer health disorders, with oxidative effects from nutritional imbalances as a significant contributing factor. Of the approximately 270 million pets in the EU, 60% have commercial pet food exclusively as their source of nutrition and therefore depend on a complete and balanced product for health and wellbeing. The PetLife project is based on a promising market and growth opportunity deriving from our current L-Cysteine derivative product line for use in plant nutrition. This latent cysteine is released into the plant gradually, providing its organism with several essential health benefits that extend to animals as well. AXEB is set to be the first in Europe and globally to validate and introduce L-cysteine derivatives as nutritional additives for animals, to solve the problem of providing cysteine without causing nutritional imbalances and weight gain. The health benefits to be proved in phase 2 validation will convince pet owners and feed manufacturers of the worth of these new added-value formulations. Our objective is to take advantage of our know-how in order to broaden the use of this innovative compound as an animal nutrient and access the EU pet food industry and European pet owners who spend up to €21,000 on each pet over its lifetime, and €55 per pet every year on veterinary care. When scaled up to industrial production, the proposed PetLife L-Cysteine derivatives will be commercialized with a target price 25% cheaper than current pet food additives, and provide more long-ranging health benefits to reduce end user veterinary expenses. Although we already possess the knowledge in biotechnology processes for molecule synthesis, we require assistance to enter the pet food market due to the rigorous regulatory approval process for new additives in the European market. The possibility of European funding will help us cross the ‘valley of death’ from development to marketplace. |
Location
Country | Spain |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Manufacturing (Industrial), Commercial |
Article published date | 2026-01-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
